Collection of PBSC by leukapheresis requires one venous access (VA) for inflow and one for outflow. The use of implantable venous access devices (IVAD) has never been reported in this setting. We retrospectively analyzed the use of IVAD for performing apheresis. The study was conducted between January 2000 and June 2005 on 64 patients (41 children) requiring intensification for treatment of a solid tumor. Mean body weight was 26 kg (range 8-91 kg) for a median age of 8.5 years (range 0.7-66 years). A total of 121 aphereses were performed (mean 1.89 apheresis/patient). The second VA was in a cubital vein in 84 procedures and was a temporary central VA in 31. Mean duration of apheresis was 3 h (range 30-274 min). Mean flow rate was 41.3 ml/min (range 12-85 ml/min). Mean collection rate was 59.2% for CD34 þ cells and 70% for mononuclear cells. The total number of CD34 þ cells collected was 2.5 Â 10 6 /kg per apheresis, and 5.9 Â 10 6 /kg per patient. Several complications occurred: one catheter-related sepsis (0.86%), four catheter occlusions (3.47%) and eight hemodynamic instabilities related to extracorporeal volume. Weight o10 kg is a risk factor for complication (P ¼ 0.0006). IVAD are effective and safe for PBSC collection. Placement of a second central VA (requiring general anesthesia for children) could be avoided.
Introduction
Autologous peripheral SCT has largely replaced BMT for the treatment of cancer in both adults and children. Cells are collected by apheresis. The technique has been widely used in France since its introduction in the early 1990s. Major advances have been made, first with the use of hematopoietic growth factors such as G-CSF, and also with the use of cell separators allowing efficient collection of blood leukocytes during extracorporeal circulation.
Several factors may contribute to the efficiency of aphereses. The two most prominent ones are (1) amount of CD34 þ cells in the blood, which follows directly from the previous phase of treatment, namely the 'mobilization' of hematopoietic cells; (2) the use of a double-lumen venous access (VA) port (either central or peripheral), allowing sufficient blood flow for cell collection (between 20 and 50 ml/min in children [1] [2] [3] rising to 100 ml/min in adults). Most patients receiving chemotherapy for malignant disease have undergone placement of a central venous catheter with implantable port or totally implantable venous access device (IVAD), which provides improved comfort for the patient and better control of infection. [4] [5] [6] [7] There is no literature addressing the feasibility of apheresis using this type of central venous device. In most French centers, a second central or peripheral venous catheter is usually required for apheresis procedures. Placement of a second central venous catheter, particularly in children in whom it is usually carried out under general anesthesia, is a rather complicated procedure. In our institution, chemotherapy is preferably administered via an IVAD, even in young, low-weight children. This IVAD is used for all subsequent treatments, including high-dose chemotherapy and peripheral stem cell rescue, 8 and for performing apheresis when marrow-ablative chemotherapy is considered.
The present study is a retrospective analysis of all apheresis procedures performed in children and adults treated at the Centre Leon Berard using IVAD devices carried out to assess the feasibility of apheresis using an IVAD. Results obtained are compared with available literature data particularly to determine whether the risk of complications is higher with IVAD than with external central venous catheters.
Patients and methods

Apheresis procedure
In our institution, the management of patients with malignant tumors receiving high-dose chemotherapy and autologous PBSC rescue involves both clinical adult or pediatric oncology services and the cell therapy unit in charge of the apheresis. The cell therapy laboratory ensures the handling, control and preservation of the hematopoietic graft.
In most patients, IVAD are inserted at diagnosis, and then used for administering various intravenous treatments (chemotherapy and supportive treatments). We use Bard titanium low-profile implanted ports with open-lumen radio-opaque intravenous ChronoFlex silicone catheters (CR Bard Inc., Salt Lake City, UT, USA). The size of the IVAD varies with the age and weight of the patient: ports of 24.8 mm in diameter and 9.4 mm in height with 6 Fr catheter (less than 1.3 mm in diameter) for patients less than 45 kg; ports of 27.2 mm in diameter and 15 mm in height with 8 Fr catheter (less than 1.6 mm in diameter) for patients more than 45 kg. Catheters are inserted in the operating room by an anesthetist. Insertion is performed under general anesthesia in children less than 15 years old, and under local anesthesia in older patients. No systematic antibiotic or anticoagulant prophylaxis is used. For apheresis, the IVAD is punctured with a 19G, 20 mm curved Huber needle (Laboratoires Pe´rouse, Ivry le temple, France).
PBSC are mobilized into the blood stream by administration of 5 mg/kg/day G-CSF for 5 days or more before apheresis collection in patients in whom the last chemotherapy is considered as a mobilizing regimen or when it has been received less than 3 weeks before. Administration of 10 mg/kg/day G-CSF for 4 days before the first apheresis (mobilization in 'stable phase') can also be performed. For adult patients, cubital veins are preferably used when suitable. If not or in children, the IVAD is used. Choice of the second vascular access device for apheresis depends on the vascular status of the patient, as systematically monitored by a nurse from the apheresis unit. Whenever possible, the second access is through a short catheter inserted in a peripheral vein, usually at the bend of the elbow (ProtectIV Plus-W; Medex, Waukesha, WI, USA). When the blood flow is reduced, insertion of a second central venous catheter is mandatory. It is either removed after completion of the apheresis or left in place for further treatment (the catheter is thus tunneled). A local anesthetic cream is applied before percutaneous puncture.
Adequate blood and CD34 þ cell counts are required. Apheresis is initiated when the peripheral blood CD34 þ cell count exceeds 20 cells/ml. Below this threshold, the decision to perform apheresis collection is shared by the clinical oncologist and the physician in charge of the apheresis unit.
Children and frail patients are hospitalized 1 day before the first apheresis for biologic control. Severe anemia (hemoglobin o90 g/l in adults and o105 g/l in children) is treated by transfusion of irradiated leukocyte-reduced packed red cells. Transfusion of platelets to 480 g/l is required only when invasive surgery is considered (catheter insertion). Electrolyte disorders such as hypocalcemia or hypomagnesemia are corrected by oral medication.
Our primary objective was to collect a total of 2 Â 10 6 CD34 þ cells per kilogram and per graft over a maximum of three sessions before initiation of high-dose therapy and hematopoietic rescue. This threshold was progressively increased to a minimum of 5 Â 10 6 CD34 þ cells per graft.
Patients are leukapheresed using a continuous-flow spectra blood separator (Gambro-BCT Inc., Blood Component Technology, Lakewood, CO, USA) following the manufacturer's instructions, with extracorporeal blood warming (36.81C) to prevent hypothermia.
Blood collections are performed by processing three total blood volumes at each 3 h session (approximately 1 total blood volume in 1 h). The flow is automatically adapted to the characteristics of the patient (sex, size, weight, hematocrit). It is limited by the robustness of the VA and the amount of acid citrate dextrose anticoagulation (ACD-A) used. The collection is discontinued after 3 h. Extracorporeal circulation is usually initiated by injection of an isotonic solution. Irradiated, leukocyte-reduced, usually CMV-negative, packed red cells are used for priming in children less than 25 kg to prevent hemodynamic instability due to an excessive ratio of extracorporeal volume (285 ml) to patient blood volume. 1 The ACD-A ratio is 1/14 in adults and 1/16 in children less than 25 kg. Systemic calcium chloride is infused to prevent hypocalcemia in children, whereas in adults it is only given at the onset of symptoms (paresthesia, nausea, vomiting and somnolence). A complete blood count is performed at completion of apheresis, as well as biochemical profile monitoring in children. The efficiency of CD34 þ cells (expressed in %) corresponds to the total number of CD34 þ cells in the final product/(number of CD34 þ cells/ml in the peripheral blood before the procedureÂ volume of blood processed (ml) Â 10).
Patients
This is a retrospective study of all adult or pediatric patients undergoing apheresis using an IVAD between January 2000 and June 2005 at the cell therapy unit of the Le´on Be´rard Cancer Center (Lyon). During this period, 64 patients (41 children and 23 adults) underwent a total of 121 aphereses using IVAD, corresponding to 1.89 aphereses per patient. Pathological data, disease stage, patient age and weight, type of catheter, mobilization procedures, infectious, mechanistic and hemodynamic complications, as well as biological data before, during and after the apheresis procedure were obtained from the clinical and nursing records of the patients and from the technical record associated with each apheresis. Major adverse events were vascular access occlusion (impaired blood flow in or out of the IVAD) 6 and infection, defined using the CDC (Center for disease Control and Prevention) criteria: positive blood culture from the central VA device associated with another positive blood culture with the same microorganism from the peripheral VA device, with no evidence of any other source of infection. Correlations between the two variables were assessed using Pearson's correlation coefficient. All statistical tests were performed using SAS software, release 8.2.
9 All tests were two-sided, with a 5% level of significance.
Results
Patient demographics are described in Table 1 . Median age was 8.5 years (range 0.7-66 years) and 11 children were less than 24-months old. The sex ratio was 1/1.13 (M/F). Median weight was 26 kg (range 6.6-91 kg) and eight patients were less than 10 kg at the time of apheresis.
The most frequent cancers were neuroblastoma (n ¼ 16), lymphoma (n ¼ 10), medulloblastoma (n ¼ 6), and Hodgkin's disease (n ¼ 6). Ten patients received several successive chemotherapy treatments with hematopoietic rescue: five grafts in five patients, two grafts in the other five.
Stem cell mobilization was achieved by administration of 5 mg/kg G-CSF after the chemotherapy regimen, or highdose CY (4 g/m 2 ) followed by G-CSF (n ¼ 10). Three were mobilized in 'stable phase'. Twelve patients received a blood transfusion on the day before apheresis (packed red cells in 10 patients and platelets in 2). On 49 occasions (42.6%), packed red cells were used for priming the extracorporeal circuit.
The IVAD was generally implanted at diagnosis (data concerning IVAD insertion were missing in 21 of the adult patients). In the 43 patients available for analysis, the median time between IVAD placement and the first apheresis was 384 days (range 1-939 days), 88% had right jugular central VA and 12% had left jugular central VA. Pediatric-sized devices were used in 31 (72%) of the 43 patients.
The second VA was achieved through a peripheral vein in 45 patients (aged 2-66 years), and through a second central venous catheter in 19 patients (aged o7 months-66 years). Second central venous catheters (10 tunneled jugular catheters and 10 nontunneled femoral catheters) were inserted on the day of the first apheresis, or the day just before. Insertion was achieved under general anesthesia in 12 patients (all less than 18 years of age).
In 49 patients (78%, 95 procedures), the IVAD route was used for the return of blood from the cell separator, whereas the withdrawal of blood was through peripheral VA in 32 patients (67 procedures) or central VA in 17 patients (28 procedures).
In 15 patients (19 procedures), the IVAD route was used for blood withdrawal and the blood was returned through a peripheral venous catheter in 13 patients (17 procedures) or a central venous catheter in 2 patients (2 procedures).
In some cases, the IVAD used for withdrawing blood from the patient failed to achieve sufficient blood flow and more than two VAs were required: in five cases (four adult patients) blood was withdrawn through a second peripheral venous catheter, with the first one being used for returning blood to the patient; in one case, the blood was returned through the central venous catheter.
In two patients (two procedures), blood withdrawal was through two peripheral VAs and the IVAD was used for returning the blood to the patient, in addition to a peripheral VA device.
In seven patients, it was necessary to switch vascular routes between the procedures: the first access used was IVAD in three patients and peripheral access in the other four.
The median blood flow was 41.3 ml/min (range 12-85 ml/ min), and the optimal blood flow of the apheresis machine was not reached in 36 procedures (24 patients). In those cases, there was a 16% mean difference (range 5.1-46%) between the maximum capacity of the machine and the actual flow through the VA device (see Figure 1 : correlation between actual flow, maximum flow expected and patient weight).
The median number of CD34 þ cells in the peripheral blood before the start of apheresis was 21.2/ml. In 23 cases, this number was reduced to less than 10 CD34 þ cells/ml.
The number of CD34 þ cells collected for each patient was 2.5 Â 10 6 CD34 þ cells/kg (range 0.3-20 Â 10 6 ) in one apheresis procedure and 5.9 Â 10 6 CD34 þ cells/kg (range 2.4-33 Â 10 6 ) when more than one apheresis procedure were performed. The median number of CD34 þ cells per ) in adults, which corresponds approximately to the numbers expected in our group. The median total volume of CD34 þ cells collected per patient was 9.9 Â 10 6 (range 0.6-33) for children and 5 Â 10 6 (range 0.8-14.2) for adults.
The median efficiency of mononuclear cells and CD34 þ cells was, respectively, 67% (mean 70%) and 55% (mean 59.2%). The CD34 þ cell efficiency was 57% in procedures where the maximum flow rate of the machine was not reached (the difference is not significant).
After the end of the apheresis, the median platelet decrease was 44 g/l (40%). The median hemoglobin decrease was 10.2 g/l (11.1%) in patients of 25 kg and over. The level did not change when packed red cells were given for priming the extracorporeal circuit (patients less than 25 kg).
Two procedures were stopped early; one because of a mechanical problem with the peripheral VA device, the other because of an infectious complication. Septic shock due to documented infection with Serratia marcescens isolated both from the IVAD and the peripheral blood was reported at the beginning of the apheresis procedure in a 35-year-old female patient with relapsed lymphoblastic lymphoma. Hemodynamic complications were reported in five other patients. An infant of 6.6 kg experienced hemodynamic instability at each of three apheresis procedures performed in a pediatric resuscitation unit; collection was thus suspended and 0.9% NaCl solution (10 ml/kg in total) administered. A second infant (10 kg body weight) who had bleeding in the area of the femoral catheter was given fluid. Three children below 15 kg had a drop in blood pressure, though they did not require cessation of the apheresis or administration of any specific treatment. In four patients, mechanical catheter failure was reported at the time of hospitalization; all problems were resolved by flushing with heparin (two cases) or with urokinase (2 ml of 5 000 UI/ml urokinase solution). No catheter thrombus was documented during apheresis. Post-collection hypocalcemia was seen in one of 79 cases (1.26%) and mild or moderate hypokalemia not requiring oral supplementation in 40 (50.63%).
The IVAD implanted for apheresis were further used for PBSC reinfusion and grafting in 43 patients. 8 In 21 patients, PBSC were not reinfused, either because of tumor progression or because the time between apheresis and the cutoff date of this study was too short.
Discussion
BMT is no longer widely used in France for autologous transplantation. Apheresis collection of PBSC is currently the most common method in this situation: there were 20% bone marrow grafts in children in 1992, versus 3% in 2003. In adults, the difference is even greater, with 75% in 1997 and only 1% in 2003. 9 The technical aspects of the procedure have been improved and complications have become less frequent.
Since effective flow rates are related to the size and the weight of the patient, the availability of adequate vascular access is one of the major determinants of apheresis efficiency. Most cancer patients have a central venous catheter implanted at diagnosis for the delivery of chemotherapy and supportive treatments. Sometimes this vascular route is used for harvesting PBSC, together with a peripheral VA [10] [11] [12] device or another temporarily inserted central venous catheter. 11, 12 However, because peripheral catheters are easy to insert and are seldom associated with complications, this method is used whenever possible. 10, 11, 13 Some groups advocate inserting non-tunneled duallumen catheters before the beginning of the apheresis procedure.
14,15 These temporary polyurethane hemodialysis catheters are semi-rigid, which helps to ensure correct placement (under local anesthesia in adults), and reduces the incidence of vessel trauma during the procedure. They are removed after apheresis, and a second central venous catheter is then inserted for grafting. Dual-lumen catheters provide high, constant blood flow and recirculation rates (median 30 ml/min in children, 15 and 61 ml/min in adults 14 ). However, frequent mechanical and infectious complications have been reported (3.6-8.92% infections and 1.8-3.5% occlusions), as well as some cases of pneumothorax at the time of catheter insertion. 14, 15 Dual-or multi-lumen tunneled catheters may also be used for both apheresis and grafting, 1, 3, [16] [17] [18] with a flow rate of approximately 40 ml/min (range 25-65 ml/min). A study by Restrepo et al. 18 using Pheres Flow triple-lumen tunneled silicone catheters in adults has reported 29% occlusions and 22% infectious complications. Gorlin et al. 1 have demonstrated that using large size catheters in children can increase the risk of complications at insertion (2 pneumothorax in 14 patients) and the incidence of thrombosis (6 cases in total, 3 necessitating removal of the device). They have proposed an algorithm for the selection of catheters adapted to the weight of the patients. Haire et al. 16 have shown that catheterization of the femoral vein using a Hickman dual-lumen catheter is associated with an increased risk of occlusion and infectious complications. Also, in most children the placement of a second venous catheter requires general anesthesia, which adds to the risk of complications. This must be taken into account when making the decision. Regarding the cost of the procedure, This should be compared to the cost of peripheral VA placement and to the absence of over-cost of using the IVAD already in place. To our knowledge, there are no published data on the use of IVAD for apheresis. The first large series published by Biffi et al. 19 in 2004 addressed the issue of IVAD for intensification, and considered that the method would be inappropriate for cytaphereses.
The efficiency of the procedure is determined from the number of mononuclear cells and CD34 þ cells in the apheresis product. Previous studies using a Gambro-BCT Spectra cell separator have reported 42.7%, 15 56.3% 20 and 59% 21 CD34 þ cells and 78% mononuclear cells. 14 In the present study, we found 55% CD34 þ cells and 67% mononuclear cells.
We identified no correlation between the size of the IVAD catheter and the efficiency of the procedure (P ¼ 0.2), but the nature of the second route is crucial. The efficiency in CD34 þ cell collection was 62% in patients with peripheral venous return, versus 49% in patients in whom a central venous return catheter had been implanted (P ¼ 0.004). This can be considered as an argument in favor of preferentially using the peripheral veins when they are suitable for phlebotomy.
Of note, the percentage of peripheral CD34 þ cells before the beginning of the procedure was below the 10 CD34 þ /ml threshold in 29 cases, principally in adult patients (39 versus 18% in children) (P ¼ 0.02).
We have shown that difficulties relating to insufficient flow rate were possible, especially in adults over 50 kg (Figure 1 ). Another vascular access device, or reduction in flow rate, may be required for these patients. This either increases the duration of the procedure to more than 3 h or requires resuming apheresis on the following day. In this case, it may be necessary to switch between the vascular routes used for blood collection and recirculation to achieve maximum flow rate. IVAD were principally used for positive pressure circulation (blood return to the patient), because most IVAD systems do not allow sufficient aspiration. In addition, diffusion of ACD-A to the patient's heart must be avoided, which discourages returning the blood through the central VA device with the proximal lumen close to the heart. The staff in-charge of aphereses must therefore be highly skilled in using vascular access devices. The early choice of VA allows adequate measures to be taken to result in an adequate outcome.
Complications encountered during the procedures were comparable to those reported in the literature. In our series, the incidence of hypocalcemia (1.26%) and hypokalemia (50%) was close to previously published data. 12, [22] [23] [24] [25] [26] As no relation to the type of vascular access was demonstrated, we principally addressed the issue of mechanical and hemodynamic complications. In children, the ratio of the extracorporeal blood volume (285 ml when using the Gambro-Spectra separator) to the total blood volume must be monitored. It was 50% for a 6-month-old child of 6.6 kg body weight. To prevent hemodynamic instability, some centers use irradiated, leukocyte-reduced packed red cells for priming the extracorporeal circuit; 1, 12, 22 others use 4% albumin. 12 The upper weight limit for priming the circuit varies between 15 12 and 25 kg. 1, 12, 26 In our series, hypotension occurred in seven procedures (6%) but treatment was required only in children of less than 10 kg.
Apheresis is sometimes associated with platelet cytopenia and possibly thrombopenia, requiring transfusion, especially in patients at risk (intracranial tumor, recent central venous catheter implantation or removal). In published studies, platelet reduction varies between 37 and 38%, 11, 24, 26 which is close to our own results (40%). Complications directly related to the vascular access were noted in 13 cases: infectious complications, intraluminal thrombosis of the catheter. Only one infectious episode was seen during the study. Comparison with the literature is difficult as most groups have reported all infectious complications occurring with the catheter (during the apheresis procedure but also in the post-graft period). 27 Hemodynamic instability was reported in eight cases. This was more frequent in small children below 10 kg (P ¼ 0.0006).
Conclusion
IVAD inserted at diagnosis can be used for apheresis, thus reducing the risks related to invasive surgery and to general anesthesia in children. Apheresis harvest using an IVAD is technically feasible regardless of the patient's age and weight, even if their use proves more problematic for patients weighing more than 50 kg. The type of VA must be determined as soon as the decision to perform apheresis is made. The option of using the IVAD already in place must be considered as it is easier for the patients, especially for children in whom this IVAD can further be used for administering high-dose treatments and PBSC rescue. 7 Finally, the use of previously implanted IVAD might provide a significant advantage both in terms of patient quality of life and cost savings and should thus be discussed in this setting. This retrospective study provides a sound basis for a future prospective work addressing the question of the use of larger devices (high-resistance totally implantable VA port systems) allowing the use of higher pressure, which should soon become available in our institution.
